JP2021521777A5 - - Google Patents

Info

Publication number
JP2021521777A5
JP2021521777A5 JP2020556877A JP2020556877A JP2021521777A5 JP 2021521777 A5 JP2021521777 A5 JP 2021521777A5 JP 2020556877 A JP2020556877 A JP 2020556877A JP 2020556877 A JP2020556877 A JP 2020556877A JP 2021521777 A5 JP2021521777 A5 JP 2021521777A5
Authority
JP
Japan
Prior art keywords
cell
enzyme
transgenic
cells
composition
Prior art date
Application number
JP2020556877A
Other languages
English (en)
Japanese (ja)
Other versions
JP7432851B2 (ja
JP2021521777A (ja
JPWO2019204269A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/027623 external-priority patent/WO2019204269A1/en
Publication of JP2021521777A publication Critical patent/JP2021521777A/ja
Publication of JP2021521777A5 publication Critical patent/JP2021521777A5/ja
Publication of JPWO2019204269A5 publication Critical patent/JPWO2019204269A5/ja
Application granted granted Critical
Publication of JP7432851B2 publication Critical patent/JP7432851B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020556877A 2018-04-16 2019-04-16 ヒトキヌレニナーゼ酵素及びその使用 Active JP7432851B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862658261P 2018-04-16 2018-04-16
US62/658,261 2018-04-16
PCT/US2019/027623 WO2019204269A1 (en) 2018-04-16 2019-04-16 Human kynureninase enzymes and uses thereof

Publications (4)

Publication Number Publication Date
JP2021521777A JP2021521777A (ja) 2021-08-30
JP2021521777A5 true JP2021521777A5 (https=) 2022-04-07
JPWO2019204269A5 JPWO2019204269A5 (https=) 2022-04-07
JP7432851B2 JP7432851B2 (ja) 2024-02-19

Family

ID=68240288

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020556877A Active JP7432851B2 (ja) 2018-04-16 2019-04-16 ヒトキヌレニナーゼ酵素及びその使用

Country Status (18)

Country Link
US (2) US11648272B2 (https=)
EP (1) EP3781179A4 (https=)
JP (1) JP7432851B2 (https=)
KR (1) KR102862473B1 (https=)
CN (1) CN112218644A (https=)
AR (1) AR115051A1 (https=)
AU (1) AU2019257340B2 (https=)
BR (1) BR112020020772A2 (https=)
CA (1) CA3096549A1 (https=)
CL (1) CL2020002650A1 (https=)
CO (1) CO2020013050A2 (https=)
EA (1) EA202092487A1 (https=)
IL (1) IL277765B1 (https=)
MX (1) MX2020010932A (https=)
SG (1) SG11202009559RA (https=)
TW (1) TWI827593B (https=)
WO (1) WO2019204269A1 (https=)
ZA (1) ZA202006077B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102271498B1 (ko) 2013-08-30 2021-07-05 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 종양 치료를 위한 키누레닌 고갈 효소의 투여
JP7080053B2 (ja) * 2014-08-29 2022-06-03 ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム 腫瘍の治療のための、キヌレニンを枯渇させる酵素の投与
US11542486B2 (en) 2016-03-02 2023-01-03 Board Of Regents, The University Of Texas System Human kynureninase enzyme variants having improved pharmacological properties
CA3154817A1 (en) * 2019-10-17 2021-04-22 James Nolan Pegylated kynureninase enzymes and uses thereof for the treatment of cancer
WO2024085280A1 (ko) * 2022-10-20 2024-04-25 서울대학교 산학협력단 신규한 키뉴레니나제 및 이의 용도

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030194721A1 (en) 2001-09-19 2003-10-16 Incyte Genomics, Inc. Genes expressed in treated foam cells
WO2003065984A2 (en) 2002-02-01 2003-08-14 Millennium Pharmaceuticals, Inc. Methods and compositions for treating cardiovascular disease
CN1330774C (zh) 2002-03-01 2007-08-08 国家人类基因组南方研究中心 犬尿氨酸水解酶多态性及其用途
WO2004094409A1 (en) 2003-03-27 2004-11-04 Lankenau Institute For Medical Research Novel ido inhibitors and methods of use
US20070207158A1 (en) 2003-06-17 2007-09-06 Harrison Roger G Conjugate for the specific targeting of anticancer agents to tumor cells or tumor vasculature and production thereof
EP2216342B1 (en) 2003-07-31 2015-04-22 Immunomedics, Inc. Anti-CD19 antibodies
JP2008237022A (ja) 2005-06-30 2008-10-09 Osaka Prefecture 非小細胞肺がんの予防・治療剤および診断薬
ES2444574T3 (es) 2006-09-19 2014-02-25 Incyte Corporation N-hidroxiamidinoheterociclos como moduladores de la indolamina 2,3-dioxigenasa
US8465743B2 (en) 2009-10-01 2013-06-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
ES2754394T3 (es) 2010-09-08 2020-04-17 Chemotherapeutisches Forschungsinstitut Georg Speyer Haus Receptores de antígenos quiméricos con una región bisagra optimizada
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
KR20120085209A (ko) * 2011-01-21 2012-07-31 인제대학교 산학협력단 트립토판 대사효소 유전자를 발현하는 줄기세포를 함유하는 면역 반응 억제용 조성물
WO2012099441A2 (ko) 2011-01-21 2012-07-26 인제대학교산학협력단 트립토판 대사효소 유전자를 발현하는 줄기세포를 함유하는 면역 반응 억제용 조성물
EP2753315B1 (en) 2011-09-07 2017-03-01 Deutsches Krebsforschungszentrum Means and methods for treating and/or preventing natural ahr ligand-dependent cancer
WO2013059593A1 (en) 2011-10-20 2013-04-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-cd22 chimeric antigen receptors
KR102271498B1 (ko) 2013-08-30 2021-07-05 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 종양 치료를 위한 키누레닌 고갈 효소의 투여
JP7080053B2 (ja) * 2014-08-29 2022-06-03 ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム 腫瘍の治療のための、キヌレニンを枯渇させる酵素の投与
US11542486B2 (en) 2016-03-02 2023-01-03 Board Of Regents, The University Of Texas System Human kynureninase enzyme variants having improved pharmacological properties

Similar Documents

Publication Publication Date Title
JP2021521777A5 (https=)
JP6484634B2 (ja) Il−15ヘテロ二量体タンパク質及びその用途
JP2016533753A5 (https=)
EP3992210A1 (en) Novel vaccines against hpv and hpv-related diseases
WO2018079740A1 (ja) 癌の治療及び/又は予防用医薬組成物
WO2024119769A9 (zh) 增强向肿瘤部位浸润能力的car-nk细胞制备及应用
US11472862B2 (en) IL13Rα2 peptide and its uses
US12551568B2 (en) Anti-claudin 6 antibody and antibody-drug conjugate
JP2022518628A (ja) Ccl21をコードする組換えラブドウイルス
WO2021027704A1 (zh) 多肽或其衍生物的应用
JP2021521777A (ja) ヒトキヌレニナーゼ酵素及びその使用
WO2022015711A1 (en) Fusion proteins of anti-pd-l1 and attenuated interferon, and compositions and therapeutic methods thereof
CN118047878A (zh) 促进巨噬细胞吞噬的嵌合抗原受体及其制备方法和应用
CN112996909A (zh) 表达pd-1结合蛋白的溶瘤病毒及其应用
JP2025515206A (ja) Utrを含む核酸構築物及びその使用
CN111118063B (zh) 以FAPα和survivin为基础的DNA及其在制备肿瘤疫苗中的应用
CN108815188A (zh) 包含间充质干细胞制剂与免疫检查点抑制剂的肿瘤治疗组合物、试剂盒及其用途
JPWO2019204269A5 (https=)
CN114712393A (zh) Hnf-1α基因修饰的间充质干细胞在防治肝癌中的用途
CN116724110A (zh) 重组溶瘤病毒及其构建方法和用途
BR112020022062A2 (pt) usos médicos
CN116270990B (zh) Adam17在制备治疗效应性cd8+t细胞分化相关疾病药物中的用途
CN113144181B (zh) 一种靶向b7h3的dna疫苗、制备方法及应用
CN116948924A (zh) 重组李斯特菌及其在抗肿瘤免疫联合治疗中的应用
CN108034669B (zh) 一种抗vegf基因、及利用其修饰的t细胞、制备方法和应用